Seattle Genetics, Inc. (NASDAQ:SGEN) Files An 8-K Other Events
Item8.01 Other Events.
On December27, 2016, Seattle Genetics, Inc. (the Company) issued
a press release announcing a clinical hold on several Phase 1
trials of vadastuximab talirine (SGN-CD33A). The Companys press
release is attached as Exhibit 99.1 to this current report and is
incorporated by reference herein.
Item9.01 Financial Statements and Exhibits.
(d) Exhibits.
| 99.1 |
Press Release of Seattle Genetics, Inc. dated December27, 2016 |
About Seattle Genetics, Inc. (NASDAQ:SGEN)
Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company’s product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). The Company’s pipeline includes other clinical-stage ADC programs, which are SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. SGN-CD33A is an ADC composed of an anti-CD33 monoclonal antibody indicated for the treatment of acute myeloid leukemia (AML). SGN-CD19A is an ADC composed of an anti-CD19 monoclonal antibody indicated for the treatment of hematologic malignancies. SGN-LIV1A is an ADC composed of an anti-LIV-1 monoclonal antibody indicated for the treatment of LIV-1-positive metastatic breast cancer. Seattle Genetics, Inc. (NASDAQ:SGEN) Recent Trading Information
Seattle Genetics, Inc. (NASDAQ:SGEN) closed its last trading session down -0.53 at 51.83 with 5,494,058 shares trading hands.